MD Conference Express ACC 2012 - (Page Cover3)
FOR INOPERABLE PATIENTS WITH SEVERE SYMPTOMATIC NATIVE AORTIC VALVE STENOSIS
A brighter future starts today
INTRODUCING THE EDWARDS SAPIEN TRANSCATHETER HEART VALVE
Groundbreaking data from The PARTNER Trial show:
• 25% absolute reduction in mortality at 2 years compared with standard therapy (including balloon aortic valvuloplasty) • Clinically significant symptomatic improvement
Complications at 2 years included:
• Stroke (13.8%) • Major vascular complications (17.4%) • Major bleeding (28.9%)*
Visit www.edwards.com/SAPIEN to learn more.
*Major bleeding is defined as an event that causes death; causes a hospitalization or prolongs hospitalization; requires pericardiocentesis or an open and/or endovascular procedure for repair or hemostasis; causes permanent disability (eg, blindness, paralysis, hearing loss); or requires transfusion of > 3 units of blood within a 24-hour period. CAUTION: Federal (United States) law restricts the Edwards SAPIEN transcatheter heart valve to sale by or on the order of a physician. This device has been approved by the FDA for specific indications for use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. CAUTION: Federal (United States) law restricts the RetroFlex 3 delivery system, RetroFlex balloon catheter, and crimper to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. See adjacent page for Important Risk Information.
Edwards Lifesciences Irvine, USA I Nyon, Switzerland edwards.com
I Tokyo, Japan I Singapore, Singapore I São Paulo, Brazil
http://www.edwards.com/SAPIEN
http://www.edwards.com/SAPIEN
http://www.edwards.com
Table of Contents for the Digital Edition of MD Conference Express ACC 2012
MD Conference Express ACC 2012
Table of Contents
Treatment of AMI in the Post-Herrick Era
The State of Hypertension Guidelines: 2012
ACRIN PA 4005: Coronary CTA in the ED Identifies Low-Risk Patients and Shortens Length of Stay
One-Year STAMPEDE Trial Results
TAVR Associated with Increased Late Mortality from Paravalvular Regurgitation
The CABG Surgery Off- or On- Pump- Revascularization Study (CORONARY)
The Moderate PE Treated with Thrombolysis Study (MOPETT)
Pacemaker Therapy In Patients With Neurally Mediated Syncope and Documented Asystole
Outcomes from the BRIDGE-ACS Trial
ROMICAT II: More Data Evaluating CT-First for Acute Chest Pain ED Triage
Elective PCI at Community Hospitals With Versus Without On-Site Surgery
Results from the TRA 2P-TIMI 50 Trial
The HOST-ASSURE Randomized Trial
New Monoclonal Antibody to PCSK9 Markedly Lowers LDL-C in Patients on Atorvastatin
Oral Rivaroxaban Alone for Symptomatic PE
Neutral Outcomes But Important Insights From FOCUS-CCTRN
Imaging
STEMI
Acute Coronary Syndrome
Antiplatelet Therapy
New Anti-Diabetes Agents Offer Promise in the Fight Against CVD
The New Hypertrophic Cardiomyopathy Practice Guidelines
MD Conference Express ACC 2012
https://www.nxtbook.com/nxtbooks/md_conference_express/acc2013
https://www.nxtbook.com/nxtbooks/md_conference_express/acc2012
https://www.nxtbookmedia.com